Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Actinic Keratosis
Interventions
DRUG

PEP005 Topical gel

0.05%, two day dose

Trial Locations (13)

2217

St George Dematology and Skin and Cancer Centre, Kogarah, Sydney

3053

Skin and Cancer Foundation, Carlton, Melbourne

4152

South East Dermatology, Belmont Specialist Centre, Carina Heights, Brisbane

6008

St John of God Dermatology, Subiaco, Perth

6100

Burswood Dermatology, Victoria Park, Perth

30263

Medaphase Inc, Newnan

32073

Park Avenue Dermatology, Orange Park

32174

Advanced Dermatology and Cosmetic Surgery, Ormond Beach

33781

Radiant Research Inc., Pinellas Park

77845

J&S Studies, College Station

85710

Radiant Research, Tucson

92117

Skin Surgery Medical Group Inc., San Diego

08075

Karen S. Harkaway, MD LLC, Riverside Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00659893 - Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2 | Biotech Hunter | Biotech Hunter